Brigitt Raux
Postdoctoral Scientist
Originally from France, Dr. Brigitt Raux completed her Master’s degree in Functional and Structural Biology at the University of Toulouse. During her Masters she completed two internships at the Mourey group in the Institute of Pharmacology and Structural Biology in Toulouse (IPBS). Her research focused on the biochemical and structural characterization of two targets involved in the virulence of Mycobacterium tuberculosis. She then worked one year at the EIPL laboratory in Marseille, on the development of inhibitors targeting digestive enzymes implicated in obesity. Brigitt later obtained her PhD in Structural Biochemistry at the University of Aix-Marseille under the supervision of Dr. Xavier Morelli in the Centre of Research in Cancerology of Marseille (CRCM). Here, she worked on the development of potent and selective inhibitors targeting the BET family of Bromodomains. In June 2018, Brigitt joined the Huber group at the Target Discovery Institute where her current research focuses on the structural and biochemical characterisation of novel targets involved in cancer and inflammatory disorders.
Recent publications
-
Slowing down fat digestion and absorption by an oxadiazolone inhibitor targeting selectively gastric lipolysis
Journal article
Point V. et al, (2016), European Journal of Medicinal Chemistry, 123, 834 - 848
-
Protein–Protein Interaction Inhibition (2P2I)-Oriented Chemical Library Accelerates Hit Discovery
Journal article
Milhas S. et al, (2016), ACS Chemical Biology, 11, 2140 - 2148
-
Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins
Journal article
Raux B. et al, (2016), Journal of Medicinal Chemistry, 59, 1634 - 1641
-
Supported inhibitor for fishing lipases in complex biological media and mass spectrometry identification
Journal article
Delorme V. et al, (2014), Biochimie, 107, 124 - 134